Carasent AB (publ)APXZF 80 PE Ratio (TTM) is 2.42 as of Jun. 29, 2026, which is 94% below its 10-year median of 38.83. GuruFocus rates APXZF with a GF Score™ of 80/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 430 Healthcare Providers & Services companies, Carasent AB (publ) ranks worse than 72.79% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-29), Carasent AB (publ)'s share price is
$0.15.
Carasent AB (publ)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06. Therefore, Carasent AB (publ)'s PE Ratio (TTM) for today is 2.42.
Good Sign:
Carasent AB (publ) stock PE Ratio (=39.48) is close to 3-year low of 37.93.
The historical rank and industry rank for Carasent AB (publ)'s PE Ratio (TTM) or its related term are showing as below:
APXZF'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 0.95 Med: 38.83 Max: 1283.33
Current: 39.48
During the past 13 years, the highest PE Ratio (TTM) of Carasent AB (publ) was 1283.33. The lowest was 0.95. And the median was 38.83.
APXZF's PE Ratio (TTM) is ranked worse than 72.79% of 430
companies
in the Healthcare Providers & Services industry
Industry Median: 21.585
vs APXZF: 39.48
During the past 3 years, the average EPS without NRIGrowth Rate was -17.90% per year.
During the past 13 years, Carasent AB (publ)'s highest 3-Year average EPS without NRI Growth Rate was 124.70% per year. The lowest was -536.20% per year. And the median was -1.60% per year.
Carasent AB (publ)'s EPS (Basic) for the
three
months ended in Mar. 2026 was $0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06.
Carasent AB (publ) (OTCPK:APXZF) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Carasent AB (publ) PE Ratio (TTM) Related Terms
Carasent AB (publ) PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APXZF vs VEEV, BTSG, TEM: PE Ratio (TTM) Comparison
For the Health Information Services subindustry, Carasent AB (publ)'s PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) PE Ratio (TTM) vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Carasent AB (publ)'s Share Price of today is $0.15.
Carasent AB (publ)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Carasent AB (publ) (APXZF) has a PE Ratio (TTM) of 2.42 as of Jun. 29, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Carasent AB (publ) and its competitors. This is 94% below median its historical median of 38.83. Over the past decade, Carasent AB (publ)'s PE Ratio (TTM) has ranged from 0.95 to 1,283.33. According to the industry distribution chart, Carasent AB (publ) ranks #313 out of 430 companies in the Healthcare Providers & Services industry, placing it in the top 72.8%.
Is Carasent AB (publ)'s PE Ratio (TTM) too high?
Carasent AB (publ)'s current PE Ratio (TTM) of 2.42 is 94% below median its 10-year median of 38.83. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 1,283.33. The Healthcare Providers & Services industry median PE Ratio (TTM) is 21.59. Carasent AB (publ)'s value of 2.42 is 88.8% below this industry median. Based on the distribution chart, Carasent AB (publ) ranks #313 out of 430 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s PE Ratio (TTM) compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #313 out of 430 companies for PE Ratio (TTM). This places Carasent AB (publ) in the lower half of its industry. The industry median PE Ratio (TTM) is 21.59. Carasent AB (publ)'s value of 2.42 is 88.8% below this benchmark. Historically, Carasent AB (publ)'s own PE Ratio (TTM) has ranged from 0.95 to 1,283.33 over the past decade. While the company's 10-year median is 38.83 vs. the industry median of 21.59, Carasent AB (publ) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Healthcare Providers & Services company?
The median PE Ratio (TTM) among Healthcare Providers & Services companies is 21.59, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current PE Ratio (TTM) of 2.42 is 88.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median PE Ratio (TTM) is 21.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current PE Ratio (TTM) is 2.42, which is 94% below median its own 10-year median of 38.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current PE Ratio (TTM) of 2.42. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current PE Ratio (TTM) is 2.42, which is 94% below median its 10-year median of 38.83 and 88.8% below the Healthcare Providers & Services industry median of 21.59. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current PE Ratio (TTM) is 2.42 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (APXZF) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.
Key valuation signals for APXZF:
PE Ratio (TTM): 2.42 (94% below median its 10-year median of 38.83)
GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
Industry Position: 88.8% below the Healthcare Providers & Services median (#313 of 430)
No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score
Get the complete analysis for APXZF
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APXZF has been successfully added to your 
